<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929420</url>
  </required_header>
  <id_info>
    <org_study_id>ry-2016-08</org_study_id>
    <nct_id>NCT02929420</nct_id>
  </id_info>
  <brief_title>A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie Capsule</brief_title>
  <official_title>A Multicenter, Randomized, Open, Parallel Controlled Clinical Study on the Efficacy and Safety of the Treatment of Cyclomastopathy With Xiaoru Sanjie Capsule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Xiaoru Sanjie capsule in
      the treatment of cyclomastopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, open and parallel controlled clinical study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the size of breast lumps</measure>
    <time_frame>after 30 days' treatment</time_frame>
    <description>Assess the size of breast lumps by breast ultrasonography or breast molybdenum target.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the size of breast lumps</measure>
    <time_frame>after 60 days' treatment</time_frame>
    <description>Assess the size of breast lumps by breast ultrasonography or breast molybdenum target.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the size of breast lumps</measure>
    <time_frame>after 90 days' treatment</time_frame>
    <description>Assess the size of breast lumps by breast ultrasonography or breast molybdenum target.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the scope of breast lumps</measure>
    <time_frame>after 30 days' treatment</time_frame>
    <description>Assess the scope of breast lumps by breast ultrasonography or breast molybdenum target.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the scope of breast lumps</measure>
    <time_frame>after 60 days' treatment</time_frame>
    <description>Assess the scope of breast lumps by breast ultrasonography or breast molybdenum target.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the scope of breast lumps</measure>
    <time_frame>after 90 days' treatment</time_frame>
    <description>Assess the scope of breast lumps by breast ultrasonography or breast molybdenum target.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the hardness of breast lumps</measure>
    <time_frame>after 30 days' treatment</time_frame>
    <description>Assess the hardness of breast lumps by breast ultrasonography or breast molybdenum target.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the hardness of breast lumps</measure>
    <time_frame>after 60 days' treatment</time_frame>
    <description>Assess the hardness of breast lumps by breast ultrasonography or breast molybdenum target.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the hardness of breast lumps</measure>
    <time_frame>after 90 days' treatment</time_frame>
    <description>Assess the hardness of breast lumps by breast ultrasonography or breast molybdenum target.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain of breast</measure>
    <time_frame>after 30 days' treatment</time_frame>
    <description>According to hyperplasia of mammary glands efficacy appraisal standard of 2002 china association of chinese medicine surgery branch.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain of breast</measure>
    <time_frame>after 60 days' treatment</time_frame>
    <description>According to hyperplasia of mammary glands efficacy appraisal standard of 2002 china association of chinese medicine surgery branch.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain of breast</measure>
    <time_frame>after 90 days' treatment</time_frame>
    <description>According to hyperplasia of mammary glands efficacy appraisal standard of 2002 china association of chinese medicine surgery branch.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all adverse reactions after taking Xiaoru Sanjie capsule</measure>
    <time_frame>after 30 days' treatment</time_frame>
    <description>Number of Participants with different adverse reactions after taking treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all adverse reactions after taking Xiaoru Sanjie capsule</measure>
    <time_frame>after 60 days' treatment</time_frame>
    <description>Number of Participants with different adverse reactions after taking treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all adverse reactions after taking Xiaoru Sanjie capsule</measure>
    <time_frame>after 90 days' treatment</time_frame>
    <description>Number of Participants with different adverse reactions after taking treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the level of estrogen</measure>
    <time_frame>after 30 days' treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the level of estrogen</measure>
    <time_frame>after 60 days' treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the level of estrogen</measure>
    <time_frame>after 90 days' treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the level of progestin</measure>
    <time_frame>after 30 days' treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the level of progestin</measure>
    <time_frame>after 60 days' treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the level of progestin</measure>
    <time_frame>after 90 days' treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the level of prolactin</measure>
    <time_frame>after 30 days' treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the level of prolactin</measure>
    <time_frame>after 60 days' treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the level of prolactin</measure>
    <time_frame>after 90 days' treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Fibrocystic Disease of Breast</condition>
  <arm_group>
    <arm_group_label>Xiaoru Sanjie capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a new recipe of traditional chinese medicineï¼› Xiaoru Sanjie capsules,three pills every time,three time a day,PO, last three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xiao Yao pills</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a kind of traditional chinese medicine that is efficient and safe to treat hyperplasia of mammary glands.
Xiaoyao pills,three pills every time,three time a day,PO,last three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiaoru Sanjie capsules</intervention_name>
    <description>Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.</description>
    <arm_group_label>Xiaoru Sanjie capsules</arm_group_label>
    <other_name>Xiaoru Sanjie capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiao Yao pills</intervention_name>
    <description>Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.</description>
    <arm_group_label>Xiao Yao pills</arm_group_label>
    <other_name>ease pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years old female patients with cyclomastopathy who signed a written informed
             consent.

          -  The subjects voluntarily entered the clinical observation whom are hospitalized
             patients or outpatients with good compliance.

          -  They have specific symptoms, such as distending pain of the breast, stabbing pain,
             dull pain and radiating pain.

          -  They have specific physical sign, for example, we can touch block gland, granular,
             nodular or cord like glands and etc..

          -  Breast ultrasound or molybdenum target show I-III class by Breast Imaging Reporting
             and Data System.

        Exclusion Criteria:

          -  Women who are pregnant or lactating, and who has the history of periarthritis of
             shoulder.

          -  Excluding breast fibrocellular tumor, breast cancer and other breast diseases.

          -  Patients with poor self coordination, mentally retarded patients, or have
             cardiovascular and cerebrovascular disease, severe organic disease, as well as the
             hematopoietic system disease or mental illness.

          -  Be judged as over middle degree depression by the Hamilton's depression scale.

          -  Allergic constitution patients, and people who are allergic to a variety of drugs.

          -  Any medical history which may interfere with the test results or increase the risk of
             patients according to the investigators.

          -  Patients who have received treatment of other diseases, and those treatment methods
             and targets may have an impact on the indicators of this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Ren, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Ren</last_name>
    <phone>13700222161</phone>
    <email>renyyyyy@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yu Ren</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Ren, MD, PhD</last_name>
      <phone>13700222161</phone>
      <email>renyyyyy@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multicenter</keyword>
  <keyword>randomized</keyword>
  <keyword>open</keyword>
  <keyword>parallel controlled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrocystic Breast Disease</mesh_term>
    <mesh_term>Breast Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

